LEVI 04
Alternative Names: LEVI-04; p75NTR-FcLatest Information Update: 21 Nov 2024
At a glance
- Originator Pfizer
- Developer Levicept
- Class Analgesics; Recombinant fusion proteins
- Mechanism of Action TrkC receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pain
Most Recent Events
- 14 Nov 2024 Efficacy and adverse events data from a phase II trial in Pain released by Levicept
- 06 Aug 2024 Efficacy and adverse events data from a phase II trial in Pain released by Levicept
- 13 Dec 2023 Levicept completes enrolment in its Phase-II clinical trials in Pain in Czech Republic,Denmark, Hong Kong, Moldova, Poland (IV) (NCT05618782)